# OnCo record enzalutamide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/enzalutamide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "enzalutamide" ;
  schema:name "Enzalutamide"@en ;
  schema:description "Enzalutamide is a second-generation androgen-receptor blocker that stops the receptor binding testosterone, entering the nucleus and switching on genes. It is approved at every stage of advanced prostate cancer, from rising PSA after surgery to castration-resistant disease, and fatigue, falls and memory problems are its main drawbacks."@en ;
  schema:url <https://onco.cc/drugs/enzalutamide/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Enzalutamide> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1996756> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enzalutamide>, <https://www.nice.org.uk/guidance/ta712>, <https://www.nice.org.uk/guidance/ta377>, <https://www.nice.org.uk/guidance/ta316>, <https://www.nice.org.uk/guidance/ta580> ;
  onco:status "approved" ;
  onco:modality "Small-molecule AR antagonist" ;
  schema:alternateName "Xtandi" ;
  onco:approval "US 2012: mCRPC after docetaxel (pre-chemo 2014)", "US 2018: Non-metastatic CRPC", "US 2019: mHSPC (ARCHES)", "US 2023: High-risk biochemical recurrence (EMBARK)" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/salivary-duct-carcinoma/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/prostate-nmcrpc/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-bcr/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:companies <https://onco.cc/companies/astellas/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/zydus/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/> ;
  onco:terms <https://onco.cc/terms/mcrpc-mhspc/>, <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/arches/>, <https://onco.cc/trials/embark/>, <https://onco.cc/trials/talapro-2/>, <https://onco.cc/trials/mevpro-1/>, <https://onco.cc/trials/nct06629779/>, <https://onco.cc/trials/nct06520345/>, <https://onco.cc/trials/nct07028853/>, <https://onco.cc/trials/nct04076059/>, <https://onco.cc/trials/nct04446117/>, <https://onco.cc/trials/nct07611110/>, <https://onco.cc/trials/nct05422911/>, <https://onco.cc/trials/nct04986423/>, <https://onco.cc/trials/nct07287150/>, <https://onco.cc/trials/nct06228053/>, <https://onco.cc/trials/nct07230106/>, <https://onco.cc/trials/nct02960022/>, <https://onco.cc/trials/nct05367440/>, <https://onco.cc/trials/nct06991556/>, <https://onco.cc/trials/nct02861573/>, <https://onco.cc/trials/nct04557449/>, <https://onco.cc/trials/nct07198633/>, <https://onco.cc/trials/nct04104776/>, <https://onco.cc/trials/nct06702995/>, <https://onco.cc/trials/nct05914116/>, <https://onco.cc/trials/nct06863272/>, <https://onco.cc/trials/nct05112965/>, <https://onco.cc/trials/nct04821622/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-prosper-nejm-2018/>, <https://onco.cc/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/> .